Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0085580 (
essential hypertension
)
14,686
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Human
NHA2
is a poorly characterized Na(+)/H(+) antiporter recently implicated in
essential hypertension
. We used a range of computational tools and evolutionary conservation analysis to build and validate a three-dimensional model of
NHA2
based on the crystal structure of a distantly related bacterial transporter, NhaA. The model guided mutagenic evaluation of transport function, ion selectivity, and pH dependence of
NHA2
by phenotype screening in yeast. We describe a cluster of essential, highly conserved titratable residues located in an assembly region made of two discontinuous helices of inverted topology, each interrupted by an extended chain. Whereas in NhaA, oppositely charged residues compensate for partial dipoles generated within this assembly, in
NHA2
, polar but uncharged residues suffice. Our findings led to a model for transport mechanism that was compared to the well-known electroneutral NHE1 and electrogenic NhaA subtypes. This study establishes
NHA2
as a prototype for the poorly understood, yet ubiquitous, CPA2 antiporter family recently recognized in plants and metazoans and illustrates a structure-driven approach to derive functional information on a newly discovered transporter.
...
PMID:Model-guided mutagenesis drives functional studies of human NHA2, implicated in hypertension. 2005 53
Human
NHA2
, a newly discovered cation proton antiporter, is implicated in
essential hypertension
by gene linkage analysis. We show that
NHA2
mediates phloretin-sensitive Na(+)-Li(+) counter-transport (SLC) activity, an established marker for hypertension. In contrast to bacteria and fungi where H(+) gradients drive uptake of metabolites, secondary transport at the plasma membrane of mammalian cells is coupled to the Na(+) electrochemical gradient. Our findings challenge this paradigm by showing coupling of
NHA2
and V-type H(+)-ATPase at the plasma membrane of kidney-derived MDCK cells, resulting in a virtual Na(+) efflux pump. Thus,
NHA2
functionally recapitulates an ancient shared evolutionary origin with bacterial NhaA. Although plasma membrane H(+) gradients have been observed in some specialized mammalian cells, the ubiquitous tissue distribution of
NHA2
suggests that H(+)-coupled transport is more widespread. The coexistence of Na(+) and H(+)-driven chemiosmotic circuits has implications for salt and pH regulation in the kidney.
...
PMID:Unconventional chemiosmotic coupling of NHA2, a mammalian Na+/H+ antiporter, to a plasma membrane H+ gradient. 2294 42
Increased renal reabsorption of sodium is a significant risk factor in hypertension. An established clinical marker for
essential hypertension
is elevated sodium lithium countertransport (SLC) activity.
NHA2
is a newly identified Na
+
(Li
+
)/H
+
antiporter with potential genetic links to hypertension, which has been shown to mediate SLC activity and H
+
-coupled Na
+
(Li
+
) efflux in kidney-derived MDCK cells. To evaluate a putative role in sodium homeostasis, we determined the effect of dietary salt on
NHA2
. In murine kidney sections,
NHA2
localized apically to distal convoluted (both DCT1 and 2) and connecting tubules, partially overlapping in distribution with V-ATPase, AQP2, and NCC1 transporters. Mice fed a diet high in sodium chloride showed elevated transcripts and expression of
NHA2
protein. We propose a model in which
NHA2
plays a dual role in salt reabsorption or secretion, depending on the coupling ion (sodium or protons). The identified novel regulation of Na
+
/H
+
antiporter in the kidney suggests new roles in salt homeostasis and disease.
...
PMID:NHA2 is expressed in distal nephron and regulated by dietary sodium. 2790 97